Transforming science into drug success stories

Summary:
4P004 is a GLP-1 analog, a potential first-in-class disease modifier drug for osteoarthritis (DMOAD), showing anti-inflammatory, anti-catabolic and anabolic properties.4P004 was developed in collaboration with the team of Prof. Francis Berenbaum (St-Antoine’s hospital in Paris, APHP and Sorbonne University) and SATT Lutech. Today, 4P004 is owned by 4P-Pharma’s SPV – 4Moving Biotech.

Milestone:
We are now entering Phase II of our study

Market:
≥ 595 Millions of people have OA in the world (Kloppenburg et al., 2020). Estimated sales per year: 3-4 Milliards/year (GlobalData: https://www.globaldata.com/osteoarthritis-7mm-market-set-to-be-worth-3-5-billion-by-2026/)

Summary:
In partnership with Delta4, an AI tech company based in Vienna (Austria), we join forces to discover and develop a drug candidate from Delta4’s platform, for the treatment of PSC.

Primary sclerosing cholangitis (PSC) is a rare liver condition, characterized by inflammation and scarring of the bile ducts leading to liver failure, and it predominantly affects individuals between 30 and 40 years old, more commonly in men. It has a low incidence and prevalence rate, ranging from 0 to 1.3 cases per 100,000 people per year, with a median survival of about 10 years without liver transplantation. The disease is more prevalent in North America and Northern Europe compared to Asia, and there is a notably higher risk among siblings of affected individuals, particularly in nonsmokers ( for review: Rawla and Samant, 2023)